ArticleNature communications2025
Substantial spillover burden of rat hepatitis E virus in humans.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Traveling with chronic viral hepatitis.Tropical diseases, travel medicine and vaccines · 2026Review
- Rocahepevirus ratti: molecular evolution, zoonotic potential and public health impact.Nature communications · 2026Review
- Environmental considerations in hepatitis E virus transmission: Is there a missing link?World journal of hepatology · 2026Review
- Hepatitis E in Wildlife: Emerging Threats to Human Health.Veterinary sciences · 2026Review
- Development of a Fully Automated, High-Throughput Molecular Assay for Detection of Rat Hepatitis E Virus in Routine Diagnostics.Journal of medical virology · 2026Article
- Performance of Elecsys Anti-HEV IgG and IgM Assays for the Detection of Acute, Recent or Past Hepatitis E Virus Infection.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Genomic characterization of novel orthohepeviruses in shrews and rats from Kenya.Microbial genomics · 2025Article
- Prevalence, Risk Factors, and Genetic Evolution of Rat Hepatitis E Virus in Small Mammals from Southwestern Yunnan, China.Biology · 2025Article
- Update on Hepatitis E Virus Infection 2025: Insights From an International Symposium.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Spillover of Rat Hepatitis E Virus into Humans: An Emerging Zoonosis?Future virology · 2025Article
- Seroprevalence and risk factors of hantavirus and hepatitis E virus exposure among wildlife farmers in Vietnam.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
The emergence of Rocahepevirus ratti genotype 1 (rat hepatitis E virus; rat HEV) in humans presents an unprecedented threat; however, the risk of rat HEV transmission to humans is not well understood. Here, we report the "Distinguishing Antibody Response Elicitation (DARE)" method, which distinguishes exposure to rat HEV. We use four study sets from China for large-scale population analysis: set 1 (hospital visit) and set 3 (ALT abnormality) from Yunnan province, a biodiversity hotspot, and set 2 (received physical examination) and set 4 (ALT abnormality) from Jiangsu province, a non-hotspot control region. rat HEV exposure risk is significantly higher in Yunnan, with 21.97% (190 of 865) in set 1 and 13.97% (70 of 501) in set 3, compared to 0.75% (9 of 1196) in Jiangsu's set 2. Six spillover infections for rat HEV are identified in set 1, with one case of abnormal ALT. The rat-1d strains carried by rats are closely related to those human infections. Our study reveals the substantial spillover burden posed by rat HEV in biodiversity hotspots and highlights the utility of DARE method for proactive surveillance of public health emergencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.